Business Context and Reporting Period
Company: Arrowhead Research Corporation (formerly InterActive Group, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2010
Business Model: Development-stage nanotechnology holding company focusing on nanomedicine. The company forms, acquires, and operates subsidiaries to commercialize innovative nanotechnologies. It provides strategic management, financing, and operational services to its portfolio.
- Majority-Owned Subsidiaries: Calando Pharmaceuticals, Inc. (70% ownership; clinical-stage RNAi therapeutics) and Unidym, Inc. (79% ownership; carbon nanotube-based transparent conductive films).
- Minority Investments: Nanotope, Inc. (23% ownership; regenerative medicine) and Leonardo Biosystems, Inc. (4.8% ownership; drug delivery).
- Non-Operating Subsidiaries: Agonn Systems, Inc. and Tego Biosciences Corporation (Tego assets sold in Dec 2009; results reported as discontinued operations).
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 |
|---|---|---|
| Revenue | $620,097 | $3,758,147 |
| Net Loss (Consolidated) | $(6,957,038) | $(19,308,452) |
| Net Loss Attributable to Arrowhead | $(5,774,048) | $(19,308,392) |
| Operating Expenses | $9,422,146 | $23,318,152 |
| Cash and Cash Equivalents (End of Period) | $6,847,162 | $2,020,224 |
| Total Assets | $12,354,542 | $7,702,174 |
| Total Liabilities | $4,276,246 | $2,844,238 |
| Stockholders' Equity | $8,078,296 | $4,857,936 |
Debt and Liquidity:
- Debt: Calando has a $500,000 unsecured convertible promissory note outstanding (10% interest, matured Nov 2010, payable on demand). No long-term debt is listed for the parent company.
- Liquidity: Cash increased by $4.8 million during the year, primarily due to financing activities. Management anticipates current cash resources will satisfy operations for at least the next twelve months.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately $3.1 million (83%) compared to 2009. The 2009 period included a $1.75 million license fee and $678,000 in inventory sales related to the IT-101 license to Cerulean Pharma, which did not recur in 2010. 2010 revenue was primarily from Unidym product sales ($415,000) and license fees ($155,000).
- Expense Reduction: Total operating expenses decreased by $13.9 million (60%).
- R&D Expenses: Dropped from $8.9 million to $1.1 million (88% decrease) due to the closure of Calando's lab facility, suspension of CALAA-02 development, and Unidym's shift to outsourced manufacturing.
- Salaries & Wages: Decreased by $3.7 million (46%) following workforce reductions (average headcount dropped from 43 in 2009 to 19 in 2010).
- Stock-Based Compensation: Decreased by $1.1 million due to option cancellations in 2009 and lower grant-date fair values in 2010.
- Net Loss Improvement: Net loss narrowed significantly from $19.3 million to $7.0 million, driven by cost-cutting measures and a non-cash gain of $1.8 million related to the change in value of derivative liabilities.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy:
- The company is executing a cash conservation strategy, scaling back financial support for subsidiaries to focus on near-term revenue opportunities.
- Future funding is expected to come from equity financings, asset sales, technology licensing, or strategic partnerships.
- Calando is continuing the Phase I clinical trial for CALAA-01 (siRNA therapeutic) but has suspended patient accrual at times to develop stability assays.
- Unidym is focusing on selling CNT inks and films and seeking manufacturing partners rather than expanding internal production.
Unusual Items:
- Derivative Liability Gain: A non-cash gain of $1.76 million was recorded due to a decrease in the fair value of derivative liabilities (warrants with antidilution provisions) issued in June 2010.
- Discontinued Operations: Results from Tego Biosciences are reported as discontinued operations following the sale of its IP assets to Luna Innovations in December 2009.
Risks and Contingencies:
- NASDAQ Compliance: The company received a deficiency letter from NASDAQ in December 2010 for failing to maintain a minimum bid price of $1.00 for 30 consecutive days. It has a 180-day grace period to regain compliance.
- Intellectual Property: Unidym's license with Rice University contains financial covenants; failure to meet them could result in termination of critical IP rights.
- Capital Needs: As a development-stage company, the firm has no assurance it can raise additional capital on favorable terms or at all.
- Debt Obligation: The $500,000 Calando note is payable on demand; failure to repay could lead to insolvency of the subsidiary.
Investor Verification Checklist
- Cash Runway: Verify if the $6.8 million cash balance is sufficient to fund operations through the next 12 months given the ongoing burn rate and lack of significant recurring revenue.
- NASDAQ Status: Monitor the company's ability to regain compliance with the $1.00 minimum bid price requirement by June 6, 2011, to avoid delisting.
- Calando Note: Confirm the status of the $500,000 convertible note payable on demand and whether an extension has been secured.
- Derivative Liability: Assess the volatility risk associated with the $2.4 million derivative liability, which fluctuates with the company's stock price and impacts net income.
- Unidym IP Covenants: Review Unidym's financial position relative to the covenants in its Rice University license agreement to ensure IP rights are not at risk of termination.
- Revenue Recurrence: Evaluate the sustainability of revenue streams, noting that 2009 revenue was heavily influenced by one-time licensing deals that did not repeat in 2010.